Commonwealth Equity Services LLC increased its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 10.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,015 shares of the biotechnology company’s stock after purchasing an additional 8,640 shares during the period. Commonwealth Equity Services LLC’s holdings in Anavex Life Sciences were worth $842,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in AVXL. Quantbot Technologies LP acquired a new stake in Anavex Life Sciences during the second quarter worth approximately $64,000. Miracle Mile Advisors LLC acquired a new stake in Anavex Life Sciences in the fourth quarter valued at approximately $98,000. Bridgefront Capital LLC acquired a new stake in Anavex Life Sciences in the third quarter valued at approximately $105,000. Janney Montgomery Scott LLC acquired a new stake in Anavex Life Sciences in the third quarter valued at approximately $108,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Anavex Life Sciences by 35.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,373 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 3,470 shares during the period. Institutional investors and hedge funds own 31.22% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have commented on AVXL. HC Wainwright raised their price objective on Anavex Life Sciences from $50.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 31st. BTIG Research reduced their price objective on Anavex Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, February 9th. Finally, StockNews.com started coverage on Anavex Life Sciences in a research note on Thursday, May 18th. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.60.
Anavex Life Sciences Stock Down 2.5 %
Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. As a group, equities research analysts expect that Anavex Life Sciences Corp. will post -0.78 earnings per share for the current year.
Anavex Life Sciences Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.
- Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.